Moderate intensity statin

ApprovedSmall molecule

YYonsei University

Moderate intensity statin is one of 38 small molecule programs targeting Shoulder pain. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Shoulder PainActive, not recruiting

Shoulder PainApproved

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Shoulder Pain

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Savella

AbbVie

Approved

1 3

Prostigmin

Merck & Co.

Approved

1 4

Xylocaine

MMEDRx USA, Inc.

Approved

5 5

Medrol

Pfizer

Approved

—6

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 7

Naropin

FFresenius Kabi Oncology Ltd.

Approved

2 8

Kenalog

BBassett Healthcare

Approved

2 9

Atropen

FFresenius Kabi Oncology Ltd.

Approved

1 10

Duragesic

CCephalon

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Neuromuscular Block

NCT07485517

Clinical

Trials by Indication[1]

Shoulder pain1 trial

Neuromuscular Blockade on Shoulder Pain of Elderly

Completed·MM.D. Anderson Cancer Center·Phase 4·NCT03210376·100 enrolled

Quality of Recovery1 trial

Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy

Completed·YYonsei University·N/A·NCT02762890·56 enrolled

Neuromuscular Block1 trial

Deep Versus Moderate Neuromuscular Blocking

Recruiting·MMenoufia University·N/A·NCT07485517·88 enrolled

Postoperative Recovery1 trial

The Effect of Deep Neuromuscular Block on the Perioperative Stress Response Reduction and Postoperative Recovery Enhancement in Robot-assisted Stomach Cancer Surgery

Completed·YYonsei University·N/A·NCT03937440·46 enrolled

Patient Satisfaction1 trial

Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction

Withdrawn·—·Phase 4·NCT02794714

1 more indication

Prevention1 trial

Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study

Recruiting·YYonsei University·Phase 4·NCT03770312·724 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Moderate intensity statin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moderate intensity statin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moderate intensity statin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

Moderate intensity statin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Shoulder pain1 trial

Quality of Recovery1 trial

Neuromuscular Block1 trial

Postoperative Recovery1 trial

Patient Satisfaction1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News